Enzolytics

Candidate: Anti-SARS-CoV-2 monoclonal antibodies for the treatment of COVID-19 Types: Fully human monoclonal antibodies targeting immutable sites confirmed as 98.71% to 99.29% conserved over the entirety of all 1 million coronavirus isolates. Enzolytics says it has confirmed that the analyzed sites are conserved sites not only on the initial virus strains but also existing in the Delta and Lambda variants, as well […]

Read more

Clinical Trial Has Found Interferon Does Not Help Adults Hospitalized With COVID-19

Cell-Infected-With-SARS-CoV

A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with COVID-19 pneumonia. In addition, in a subgroup of patients who required high-flow oxygen, investigators found that interferon beta-1a was associated with more adverse events and worse outcomes. These findings were published today (October 18, […]

Read more

Scientists discover a highly potent antibody against SARS-CoV-2

antibody

Scientists at Lausanne University Hospital (CHUV) and EPFL have discovered a highly potent monoclonal antibody that targets the SARS-CoV-2 spike protein and is effective at neutralizing all variants of concern identified to date, including the delta variant. Their findings are published in the journal Cell Reports. The newly identified antibody was isolated using lymphocytes from COVID-19 patients enrolled in the ImmunoCoV […]

Read more

Antibodies are less effective against delta variant

coronavirus and antibody

Lab tests suggest the delta variant escapes immune responses more easily than alpha The delta variant of the coronavirus is less sensitive than other common variants to antibodies in the blood of people who have previously been infected or vaccinated, researchers have found. The study, published in Nature, also found that the delta variant is more efficient at replicating and better at […]

Read more

The Next Treatment for COVID-19 Could Already Be at Your Local Pharmacy

drugs

Existing Drugs Kill SARS-CoV-2 in Cells Since the beginning of the pandemic, researchers worldwide have been looking for ways to treat COVID-19. And while the COVID-19 vaccines represent the best measure to prevent the disease, therapies for those who do get infected remain in short supply. A new groundbreaking study from the University of Michigan reveals several drug contenders already in […]

Read more

Pfizer, Merck launch large new trials of oral COVID-19 drugs

COVID-19 drugs

Dive Brief: Pfizer and Merck & Co. each launched pivotal clinical studies of new experimental oral COVID-19 drugs, building on previous work to provide outpatient alternatives for patients. Merck is studying whether its medicine, molnupiravir, can prevent COVID-19 in adults who live with a symptomatic patient with a confirmed coronavirus infection. The trial will include about 1,300 patients who will take molnupiravir […]

Read more

Double vaccination halves risk of long COVID, study finds

Corona Vaccine

Adults who have received a double vaccination are 49% less likely to have Long COVID should they contract a COVID-19 infection, a new study finds. Researchers at King’s College London analysed data from participants logging their symptoms, tests and vaccines on the UK ZOE COVID Symptom Study app between 8th December 2020 and 4 July 2021, including 1,240,009 (first dose) […]

Read more

Synthetic Peptide Mimics: Possible New Antivirals Against COVID-19 and Herpes

Peptoids-Pierce-the-Virus

In addition to antibodies and white blood cells, the immune system deploys peptides to fight viruses and other pathogens. Synthetic peptides could reinforce this defense but don’t last long in the body, so researchers are developing stable peptide mimics. Today, scientists report success in using mimics known as peptoids to treat animals with herpes virus infections. These small synthetic molecules […]

Read more